All Resources
Our resource hub to discover reports, policy papers and other forms of informative content
Filter by
Two years is too long – Understanding Canada’s Drug Access Pathway
Canadians wait two years for access to new medicines through our public drug plans. That’s a full year longer than patients in most other peer countries. Two years can feel…
Developing a Canadian managed entry approach for new innovation: What can Canada learn from Europe?
…plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients….
Innovative Access Arrangements and Managed Entry
A growing number of payers in many countries are looking to managed entry agreements (MEAs) and other innovative access arrangements (IAAs) to allow rapid access to medicines that address significant…
